SCOPE 2随机试验:两种自膨胀瓣膜经导管主动脉瓣置换的比较
SCOPE 2试验在6国23中心随机分配796例≥75岁有经股动脉TAVR指征的患者,比较ACURATE neo与CoreValve Evolut瓣膜。ACURATE neo在1年全因死亡或卒中方面未达到非劣效,但30天新永久起搏器植入率更低,而30天和1年心源性死亡及30天中重度主动脉瓣反流更高。
要点
- ACURATE neo相比CoreValve Evolut未达到1年全因死亡或卒中的非劣效。
- ACURATE neo的30天新永久起搏器植入率显著更低(10.5% vs 18.0%)。
- ACURATE neo与更多30天中重度主动脉瓣反流及30天和1年心源性死亡相关。
核心结论
- 经股动脉TAVR使用自膨胀ACURATE neo在1年全因死亡或卒中方面未达到相比CoreValve Evolut的非劣效。
- ACURATE neo与新永久起搏器植入率更低相关,但次要分析显示中重度主动脉瓣反流和心源性死亡增加。
研究设计与样本
- SCOPE 2为随机试验,2017年4月至2019年4月在6国23中心进行。
- 纳入≥75岁有经股动脉TAVR指征的患者,随机分配至ACURATE neo组(n=398)或CoreValve Evolut组(n=398)。
- 主要终点为1年全因死亡或卒中,检验ACURATE neo的非劣效性;关键次要终点为30天新永久起搏器植入,检验优效性。
- 796例随机患者平均年龄83.2±4.3岁,平均STS预测死亡风险评分4.6±2.9%,778例(98%)有临床随访信息。
主要发现
- 1年内主要终点在ACURATE neo组发生15.8%,CoreValve Evolut组13.9%(绝对风险差1.8%,单侧95%置信上限6.1%;非劣效性P=0.0549)。
- 30天新永久起搏器植入率ACURATE neo组10.5%,CoreValve Evolut组18.0%(绝对风险差-7.5% [95% CI, -12.4 to -2.60];P=0.0027)。
- 主要终点各组成部分无显著差异。
- 30天心源性死亡ACURATE neo组2.8% vs CoreValve Evolut组0.8%(P=0.03),1年8.4% vs 3.9%(P=0.01)。
- 30天中重度主动脉瓣反流ACURATE neo组10% vs CoreValve Evolut组3%(P=0.002)。
临床怎么用
- 对于有经股动脉TAVR指征的症状性重度主动脉瓣狭窄患者,选择ACURATE neo需权衡起搏器植入风险与瓣膜反流及心源性死亡风险。
- CoreValve Evolut在1年全因死亡或卒中方面可能更优,但起搏器植入率更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Few randomized trials have compared bioprostheses for transcatheter aortic valve replacement, and no trials have compared bioprostheses with supra-annular design. The SCOPE 2 trial (Safety and Efficacy Comparison of Two TAVI Systems in a Prospective Randomized Evaluation 2) was designed to compare the clinical outcomes of the ACURATE neo and CoreValve Evolut bioprostheses for transcatheter aortic valve replacement. METHODS: SCOPE 2 was a randomized trial performed at 23 centers in 6 countries between April 2017 and April 2019. Patients ≥75 years old with an indication for transfemoral transcatheter aortic valve replacement as agreed by the heart team were randomly assigned to receive treatment with either the ACURATE neo (n=398) or the CoreValve Evolut bioprostheses (n=398). The primary end point, powered for noninferiority of the ACURATE neo bioprosthesis, was all-cause death or stroke at 1 year. The key secondary end point, powered for superiority of the ACURATE neo bioprosthesis, was new permanent pacemaker implantation at 30 days. RESULTS: Among 796 randomized patients (mean age, 83.2±4.3 years; mean Society of Thoracic Surgeons Predicted Risk of Mortality score, 4.6±2.9%), clinical follow-up information was available for 778 (98%) patients. Within 1 year, the primary end point occurred in 15.8% of patients in the ACURATE neo group and in 13.9% of patients in the CoreValve Evolut group (absolute risk difference, 1.8%, upper 1-sided 95% confidence limit, 6.1%; P=0.0549 for noninferiority). The 30-day rates of new permanent pacemaker implantation were 10.5% in the ACURATE neo group and 18.0% in the CoreValve Evolut group (absolute risk difference, -7.5% [95% CI, -12.4 to -2.60]; P=0.0027). No significant differences were observed in the components of the primary end point. Cardiac death at 30 days (2.8% versus 0.8%; P=0.03) and 1 year (8.4% versus 3.9%; P=0.01), and moderate or severe aortic regurgitation at 30 days (10% versus 3%; P=0.002) were significantly increased in the ACURATE neo group. CONCLUSIONS: Transfemoral transcatheter aortic valve replacement with the self-expanding ACURATE neo did not meet noninferiority compared with the self-expanding CoreValve Evolut in terms of all-cause death or stroke at 1 year, and it was associated with a lower incidence of new permanent pacemaker implantation. In secondary analyses, the ACURATE neo was associated with more moderate or severe aortic regurgitation at 30 days and cardiac death at 30 days and 1 year. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03192813.
引用
- Tamburino C, Bleiziffer S, Thiele H, et al. Comparison of Self-Expanding Bioprostheses for Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis: SCOPE 2 Randomized Clinical Trial. Circulation. 2020. PMID: 33054367. doi:10.1161/CIRCULATIONAHA.120.051547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。